Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OLMA
Strong SellOlema Pharmaceuticals, Inc. · Healthcare · United States · $913M · Avg Vol: $9M/d
COMPANY DESCRIPTION
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel targeted therapies for women's cancers. Its competitive edge derives from a focused pipeline of proprietary small molecule candidates, particularly in endocrine-sensitive tumor biology, addressing significant unmet medical needs. Olema is a high-risk, high-reward biopharma player aiming to deliver differentiated therapeutic options within the oncology landscape.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | 6.3M | — |
| EPS | -1.80 | -1.21 | -2.14 | -2.20 | -1.87 | — | -2.12 | -2.42 | -2.69 | — |
| Shares | — | 87.3M | 55.0M | 74.3M | 81.4M | -6.8% | 87.5M | — | — | — |
| Debt | — | 2.6M | 2.4M | 1.4M | 4.2M | 17.8% | 3.7M | — | — | — |
| Equity | — | 197.5M | 253.9M | 409.0M | 478.6M | 34.3% | — | — | — | — |
| Op CF | — | -82.1M | -83.7M | -104.4M | -146.7M | — | -164.7M | — | — | — |
| Inv CF | — | 91.5M | -4.9M | -93.5M | -155.8M | — | — | — | — | — |
| Fin CF | — | 0.5M | 133.4M | 268.8M | 211.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OLMA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OLMA | Olema Pharmaceuticals, Inc.(you) | $913M | 5 | Strong Sell |
| WVE | Wave Life Sciences, Inc. | $1.0B | 2 | Strong Sell |
| ODTX | Odyssey Therapeutics, Inc. | $1.2B | 5 | Strong Sell |
| ANNX | Annexon, Inc. | $959M | 10 | Strong Sell |
| OBX | Obsidian Therapeutics, Inc. | $1.2B | 7 | Strong Sell |
| SANA | Sana Biotechnology, Inc. | $1.1B | 8 | Strong Sell |
| PROK | ProKidney Corp. | $643M | 4 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $701M | 9 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 9 | Strong Sell |
| SGP | SpyGlass Pharma, Inc. | $878M | 15 | Strong Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.7%